Oligonucleotide and Parylene Surface Coating of Polystyrene and ePTFE for Improved Endothelial Cell Attachment and Hemocompatibility by Schleicher, Martina et al.
Hindawi Publishing Corporation
International Journal of Biomaterials
Volume 2012, Article ID 397813, 14 pages
doi:10.1155/2012/397813
Research Article
Oligonucleotideand ParyleneSurface Coating of
Polystyreneand ePTFEforImproved EndothelialCell
Attachment andHemocompatibility
Martina Schleicher,1 Jan Hansmann,2 BentsianElkin,2 Petra J. Kluger,2
Simone Liebscher,1 A gn e sJ .T .H u be r , 1 OlafFritze,1 ChristineSchille,3
Michaela M¨ uller,2 KatjaSchenke-Layland,2,4 MartinaSeifert,5,6 Heike Walles,2
Hans-PeterWendel,1 andUlric hA.S t oc k 1
1Department of Thoracic, Cardiac and Vascular Surgery, University Hospital, Hoppe-Seyler-Strasse 3, 72076 Tuebingen, Germany
2Fraunhofer Institute for Interfacial Engineering and Biotechnology, Nobelstrasse 12, 70569 Stuttgart, Germany
3Department of Prosthodontics, Section of Medical Materials and Technology, University Hospital, Osianderstrasse 2-8,
72076 T¨ ubingen, Germany
4Inter-University Centre for Medical Technology (IZST), Eberhard Karls University, Silcherstrasse 7, 72076 Tuebingen, Germany
5Institute of Medical Immunology, Charit´ eU n i v e r s i t¨ atsmedizin Berlin, F¨ ohrer Straße 15, 13353 Berlin, Germany
6Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charit´ eU n i v e r s i t¨ atsmedizin Berlin, F¨ ohrer Straße 15,
13353 Berlin, Germany
Correspondence should be addressed to Ulrich A. Stock, ulrich.stock@med.uni-tuebingen.de
Received 15 July 2011; Revised 10 November 2011; Accepted 14 November 2011
Academic Editor: Rolf Larsson
Copyright © 2012 Martina Schleicher et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
In vivo self-endothelialization by endothelial cell adhesion on cardiovascular implants is highly desirable. DNA-oligonucleotides
are an intriguing coating material with nonimmunogenic characteristics and the feasibility of easy and rapid chemical fabrication.
The objective of this study was the creation of cell adhesive DNA-oligonucleotide coatings on vascular implant surfaces. DNA-
oligonucleotides immobilized by adsorption on parylene (poly(monoaminomethyl-para-xylene)) coated polystyrene and ePTFE
were resistant to high shear stress (9.5N/m2) and human blood serum for up to 96h. Adhesion of murine endothelial progenitor
cells, HUVECs and endothelial cells from human adult saphenous veins as well as viability over a period of 14 days of HUVECs on
oligonucleotide coated samples under dynamic culture conditions was signiﬁcantly enhanced (P<0.05). Oligonucleotide-coated
surfaces revealed low thrombogenicity and excellent hemocompatibility after incubation with human blood. These properties
suggestthesuitabilityofimmobilizationofDNA-oligonucleotidesforbiofunctionalizationofbloodvesselsubstitutesforimproved
in vivo endothelialization.
1.Introduction
Current blood vessel replacement concepts, which use either
prosthetic or biological grafts, achieve excellent mid-term
results. The clinical application, however, is accompanied by
a variety of limitations. Biological conduits (e.g., autologous
greater saphenous vein) have better hemodynamic charac-
teristics and avoid long-term anticoagulation but are limited
in availability. On the long term, however, they fail due to
intimal hyperplasia and ﬁbrosis. Allograft transplants such
as superﬁcial femoral arteries have optimal hemodynamic
properties, avoid any anticoagulation, and are resistant to
infections to a certain extent. However, due to tissue scarcity,
their availability is limited. In general, 5–30% of patients
have no suitable autologous grafts available due to previous
use or concomitant disease. In these cases, expanded polyte-
traﬂuoroethylene (ePTFE) grafts are used. However, despite
their prevalence, these grafts have a lower patency rate due to2 International Journal of Biomaterials
noncompliance, thrombogenic surface, and the tendency to
form intimal hyperplasia in particular in anastomotic areas
[1]. None of the currently available blood vessel substitutes
possess any regenerative or growth potential. This shortcom-
ing is crucialespecially forthe treatmentof pediatric patients
and grafts with repeated injury (e.g., hemodialysis shunts).
The multidisciplinary approach of tissue engineering
might oﬀer an attractive pathway to overcome these short-
comings and develop blood vessel substitutes identical or
similartonativehumanarteries.Invasculargrafts,aninvitro
established autologous endothelial cell layer on the implant
surface prior to implantation provides an excellent barrier
between the synthetic material and the blood ﬂow and has
been reported to reduce thrombosis and intimal hyperplasia
[2–4]. Overcoming these limitations will result in a distinct
improvement of graft performance and patency [2–5].
Indeed, clinical studies have demonstrated that such grafts
c a nf u n c t i o na sw e l la sa u t o l o g o u sv e i ng r a f t s[ 6]. However,
this concept imposes a variety of demands for successful
transfer from the preclinical large animal setups to the clini-
cal arena. Due to the high risk of bacterial and fungal infec-
tion throughout the entire in vitro culture (which takes up to
6 weeks from cell harvest to implantation of the engineered
product),theprocessrequiresacost-intensiveinfrastructure.
Accordingly, ongoing research focuses on the develop-
ment of facilitated spontaneous in vivo endothelialization of
vascular implants [7–11]. Several pathways are conceivable
to achieve endothelialization in vivo. One is the capture,
immobilization and adhesion of circulating endothelial (EC)
or endothelial progenitor cells (EPC) from the blood stream.
An alternative is promotion of transanastomotic ingrowth of
endothelial cells from the native vessel on and into the graft.
Both require a suitable graft surface for cell adhesion and
proliferation. However, it is reported that EC do not adhere
to currently available vascular graft materials like ePTFE and
polyethylene terephtalate (Dacron) [12, 13]. Furthermore,
transanastomotic ingrowth of EC in currently used vascular
grafts does not exceed 1-2cm even after years of clinical
implantation [14]. Hence, materials that promote in situ
endothelialization of cardiovascular implants (without inti-
mal hyperplasia or thrombus formation during endothelium
development)wouldbehighlydesirable.Diﬀerentapproach-
es exist, mostly using extracellular-matrix- (ECM-) derived
proteins or peptides with functional domains of ECM pro-
teins [7].
Another intriguing coating material for implant surfaces
is deoxyribonucleic acid (DNA). DNA is a naturally occur-
ring material with a homogenous molecular structure in all
vertebrate species [15, 16]. DNA is nontoxic with little or no
immunogenicity in contrast to other biological antigens like
proteins and sugars [15, 17, 18]. Another advantage of DNA
molecules are their easy and rapid chemically synthetization.
Use of DNA as coating material has already been suggested
for dental applications [19], and a DNA-chitosan complex
was used as scaﬀold material for tissue engineering [20].
Van Den Beucken et al. fabricated multilayered DNA coat-
ings consisting of poly-D-lysine (PDL) or poly(allylamine
hydrochloride)(PAH)andDNAanddemonstratedincreased
proliferation of primary rat dermal ﬁbroblasts (RDFs) and
cyto- as well as histocompatibility of the multilayered DNA
coatings [21]. Challenges in application of DNA for surface
functionalization are the easy nucleolytic degradation of the
substance and its solubility in aqueous solutions [19]. Fur-
thermore, DNA is an optimal material for immobilization of
additional growth or adhesion factors, as DNA oﬀers acces-
sible functional groups for chemical coupling reactions and
the possibility to incorporate molecules via groove binding
and intercalation [22, 23].
Apart from controlled cell adhesion, the coating matrix
needs to possess excellent mechanical properties in terms of
ﬂexibility and long-lasting in vivo adherence to the implant
surface. These properties are known to be supplied by poly
(p-xylylene) (PPX) and its derivates, known by their com-
mercial trade name as parylenes [24, 25]. Parylenes can be
conformally coated onto irregular substrates by a vapor de-
position process and are chemically inert and nonbiodegrad-
able. The FDA has already recognized some parylenes, such
as Parylene C and Parylene N, as Class VI polymers for coat-
ing implanted medical devices due to their biocompatibility
[26, 27].
Here,wereportaconceptofastableDNAcoatingandEC
and EPC adhesion on DNA coatings using continuous shear
stress application.
2.MaterialsandMethods
2.1. Oligonucleotides. Oligonucleotides were synthesized by
TIBMolbiol(Berlin,Germany).Assingle-sequence5 -GGG-
AGCTCAGAATAAACGCTCAACAACCCGTCAACGAAC-
CGGAGTGTGGCAGGTTCGACATGAGGCCCGGATC-3 
was used. The DNA oligonucleotide library contained a 40-
base central random sequence: 5 - GAATTCAGTCGGAC-
AGCG-N40-GATGGACGAATATCGTCTCCC-3 .F o rd e -
tection, oligonucleotides were 5 -labeled with 6-carboxyﬂu-
orescein (6FAM). For immobilization, a 5 -C12-NH2 modi-
ﬁcation was used.
2.2. Cells and Culture. Murine embryonic EPC (eEPC) line
T17b cells [28]w e r ec u l t u r e di nﬂ a s k sp r e c o a t e dw i t h0 . 1 %
gelatin. The culture medium consisted of DMEM (4.5g/L
glucose, Lonza, K¨ oln, Germany) supplemented with 20%
FCS, 0.1mmol/L β-mercaptoethanol (Serva, Heidelberg,
Germany), 1mmol/L nonessential amino acids (Gibco,
Paisley, UK), 100U/mL penicillin, 100μg/mL streptomycin
(Gibco, Paisley, UK), and 2mmol/L L-glutamine (Lonza,
K¨ oln, Germany).
Human umbilical vein endothelial cells (HUVECs) were
cultured in VascuLife VEGF Culture Medium containing 2%
FCS (Lifeline Cell Technology, Walkersville, USA).
Human ECs were harvested from human saphenous
veins. 4 to 5cm long remnants of saphenous veins from pa-
tients undergoing aortocoronary bypass procedures were
used as a cell source. Tissue procurement and use were ap-
proved by our local ethics committee and informed consent
was obtained. The veins were cannulated, ﬂushed with
DMEM (4.5g/L glucose, Lonza, K¨ oln, Germany), and ﬁlled
with 0.2% collagenase A (Roche, Mannheim, Germany).International Journal of Biomaterials 3
Cells were harvested after 20min of collagenase incubation
at 37◦C, 5% CO2. The culture medium consisted of DMEM
(4.5g/L glucose, Lonza, K¨ oln, Germany) supplemented with
recombinantbasic ﬁbroblastgrowth factor(bFGF,10ng/mL;
Boehringer, Ingelheim, Germany), 100U/mL penicillin,
100μg/mL streptomycin (Gibco, Paisley, UK), and 10% FCS.
2.3. Parylene Deposition Process. Standard ePTFE vascular
prostheses were obtained from Jotec GmbH, Hechingen,
Germany (FlowLine Bipore and FlowLine Bipore Heparin),
and ePTFE patch material from W.L. Gore & Associates, Inc.,
Flagstaﬀ, Arizona, USA (Gore-Tex Cardiovascular Patch).
ePTFEwasactivatedusingmicrowaveplasma(400W,hydro-
gen and nitrogen in equal parts, 30s) prior to coating with
parylenes. Poly (monochloro-para-xylene) (“Galxyl C”-pa-
rylene C, from Galentis S.P.A., Marcon, Italy) and poly
(monoaminomethyl-para-xylene) (diX AM-aminoparylene,
from Kisco Conformal Coating Ltd., D¨ usseldorf, Germany)
werecoatedonpolystyrenedishes,polypropylenesheets,and
activated ePTFE using a chemical vapour deposition (CVD)
processinaPDS2010coater(SCSSpecialtyCoatingSystems,
Indiana, USA). A general description of parylene CVD proc-
esses is given by Lahann [29]. This technique enables thin
homogeneous and conformal deposition on a variety of sub-
strates.Depositionisperformedundervacuumatroomtem-
perature. A thin (ca. 0.1μm) diX AM coating was deposited
onto a thicker (ca. 2μm) intermediate layer of inert Parylene
C according to recommendations from the diX AM manu-
facturer.Afterdeposition,thesampleswerestoredinthedark
using argon atmosphere to avoid amine’s oxidation.
2.4. Surface Characterization
2.4.1.ParyleneThicknessDetermination. Thethicknessofthe
intermediate Parylene C layer was determined by both grav-
imetry and ellipsometry on reference samples. In the ﬁrst
case, the mass increase of an aluminum foil which was pary-
lene coated in the same deposition run was determined. For
ellipsometry, single crystalline Si substrates were used. The
thickness of diX AM parylene top coatings was determined
by ellipsometry only. The ellipsometric measurements were
performed on a SE 801 spectroscopic ellipsometer (Sentech
Instruments GmbH, Berlin, Germany).
2.4.2. XPS Measurements. The samples were stored in dark
under argon and transferred into the XPS apparatus within
24h of deposition. The surface elemental composition was
veriﬁed by X-ray photoelectron spectroscopy (XPS) analysis
using an Axis Nova system (Kratos Analytical, Manchester,
UK) with monochromatic Al Kα X-Ray source. For all
samples,overviewspectraanddetailedspectraofallelements
found in the overview were recorded.
2.4.3. ESR Measurements. For determination of the number
of chemically available amino groups on the diX AM surface
electron spin resonance spectroscopy (ESR) in combination
with chemical derivatization was applied (similar technique
was used by Samal et al. [30] for qualitative detection of
surface functionalization). First, functionalized stable free
radicals (4-carboxy-TEMPO, Sigma-Aldrich) were bound to
surface amino groups via an EDC-mediated reaction. Subse-
quently, the number of radicals in the sample was measured
using ESR. Polypropylene ﬁlm samples (45 × 90mm) coated
on both sides with diX AM were incubated for 24 hours with
0.65mml/L 4-carboxy-TEMPO, 1.55mg/mL EDC in 0.1M
MES buﬀer (pH 5.0) at room temperature. After a thorough
washing, the ﬁlms were dried, tightly rolled, and then put
into the sample holder tube of the ESR device (MS200,
Magnettech GmbH). To obtain the absolute number of spins
in the sample, the double integral of the measured signal was
related to that of a Cr(III) standard. The number of spins
measured should then equal the number of amino groups
having reacted with the carboxy moiety of the 4-carboxy-
TEMPO.
2.4.4. Contact Angle Measurements. Contact angle measure-
ments were performed to determine the changes in wetta-
bility of the prepared surfaces. The captive bubble technique
was chosen for analyses because the surfaces were constantly
in contact with ﬂuid media. The coated samples were com-
pletely immersed in PBS with the coated side face down.
The captive bubble contact angle measurements were taken
at 22◦C using a video capture system (OCA 40, DataPhysics
Instruments GmbH, Filderstadt, Germany). An air bubble
was brought in contact with the solid sample from below.
After a few seconds, the static contact angle near the three-
phaselinewasmeasured.Foreachsample,atleastsixcontact
angles were measured.
2.5. Oligonucelotide Immobilization on diX AM-Coated Sur-
faces. If not stated diﬀerently, 1.7μM DNA-oligonucleotides
were applied to the diX AM-coated surface in HEPES buﬀer
(20mM, pH 7.0) at room temperature. After 2h, Tris-HCl
was added to a concentration of 50mM and incubated for
15min. For experiments with cell incubation, the surfaces
were washed with 0.2% BSA. Then, a triple washing step
with PBS followed. For cell experiments, an incubation with
aPBS-antibioticsolution(10mLPBSwith0.5mLantibiotic-
solution: 0.3mg amikacin, 0.75mg ﬂucytosine, 0.3mg van-
comycin, 0.075mg ciproﬂoxacin, 0.3mg metronidazole) for
24h at 4◦Cw a sp e r f o r m e d .
2.6. Shear Stress Resistance Test. DiX AM-coated polypropy-
lene sheets with applied oligonucleotides (0.5μM) were ex-
posed to ﬂow-induced shear stress for 1h at 37◦Ci nac l o s e d
circular system. The system consisted of silicon tubing, a
ﬂuid reservoir, a peristaltic pump, and a following vessel to
attenuate pump-induced pressure variability. The test ﬂuid
consisted of 1000ppm xanthan gum. Wall shear stress for
1000ppm Xanthan gum, a non-Newtonian power-law ﬂuid
[31], was calculated as follows. For a non-Newtonian power-
law ﬂuid applies
τzr = kγn,( 1 )
where τzr is the shear stress in a tube at length z and radius
r and γ the shear rate [32]. Shear-rate-dependent shear stress4 International Journal of Biomaterials
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Figure 1: Shear stress dependency on shear rate of 1000ppm
Xanthan gum measured by rotational rheometry.
of the xanthan gum solution was determined by rotational
rheometry (UDS 200, Physica, Ostﬂidern) using the follow-
ing settings: shear rate 0.01–8001/s, 50 measurement points,
measurement duration per point 10s, three individual
1000ppm Xanthan gum solutions. From the measurement,
the following values were gained: k = 0.0924Pa ∗ sn and
n = 0.5212 (Figure 1). To achieve a wall shear stress of
τwall = 9.5 N/m2 in a tube with a radius of R = 0.135cm,
the required ﬂow rate Q was calculated as follows [32]:
Q =
πR3
1/n+3

τwall
k
1/n
= 11.4cm 3/s. (2)
2.7. Serum Stability. DiX AM coated with oligonucleotides
(0.5μM) was incubated with serum derived from fresh hu-
man blood for 15min, 24h, 48h, 72h, and 96 hours at
37◦C. Serum was changed every 24 hours. Amount of oligo-
nucleotide remaining on diX AM surface was determined.
2.8. Oligonucleotide Detection. Oligonucleotides were modi-
ﬁed with 6FAM and could be detected by a ﬂuorescence mi-
croplate reader (Mithras LB 940, BertholdTech, Bad Wild-
bad, Germany). For conﬁrmation of the results and better
quantiﬁcation, an ELISA system was developed, using an
antiﬂuorescein antibody (Molecular Probes, Cat# A-889,
Eugene, USA) and an alkaline-phosphatase-conjugated sec-
ondary antibody (ZYMED Laboratories, Invitrogen, Cat#
65-6122, Carlsbad, USA). Incubation time was 2h at room
temperature each. As substrate Alkaline Phosphatase Yellow
(pNPP) Liquid Substrate System for ELISA (Sigma) was
used.
2.9. Dynamic Cell Adhesion Test. Oligonucleotides were
applied to marked areas or the whole surface of diX AM
coated Petri-dishes or diX AM-coated 12-well plates. Petri-
dishes were incubated with 0.05 ∗ 106 cells for 1–2.5h
at 37◦C, 5% CO2 in cell-corresponding or experiment-de-
pendent medium or buﬀer on a rocking orbital shaker (The
Belly Button, Stovall Life Science Inc. Greensboro, USA).
Following medium exchange to remove nonadherent cells,
Petri-dishes were inspected by phase-contrast microscopy
(Zeiss Axio Observer Z1, Germany). Cells in images with
the same area were counted. An alamarBlue assay (AbD
Serotec, Oxford, UK) was performed after 22h to determine
the relative number of metabolically active adherent cells.
150μL alamarBlue reagent were added to the samples in
1.5mL medium and incubated for four hours at 37◦Ca n d
5% CO2. Two times 100μL of each sample were pipetted
into a clear ﬂat bottom microplate and measured at 530nm
extinction and 600nm emission wavelength (Mithras LB
940, BertholdTech, Bad Wildbad, Germany).
2.10. Staining of Adhesion Markers. Oligonucleotides were
applied to marked areas of diX AM coated Petri-dishes. Ol-
igonucleotide-coated and diX AM-coated Petri-dishes and
tissue-culture Petri-dishes were incubated with 0.05 ∗ 106
HUVECs at 37◦C, 5% CO2 in medium containing FCS on a
rocking orbital shaker (The Belly Button, Stovall Life Science
Inc, Greensboro, USA). After one hour medium including
non-adherent cells was removed. Adherent cells were ﬁxed
with 4% paraformaldehyde (Sigma) for 10min at room tem-
perature. After a washing step with PBS (Lonza), PBS con-
taining 2% FCS and 0.1% Triton (Sigma) was applied for
15min. Samples were incubated over night at 4◦C with the
primary antibodies (anti-vinculin or CD49e (Integrin alpha
5), abcam, Cambridge, UK) in PBS containing 2% FCS and
0.1% Triton. After a washing step, the secondary antibody
(Goat polyclonal Secondary Antibody to Mouse IgG-H&L
(Chromeo 488), abcam, Cambridge, UK) was applied for 1h
at 37◦C. Cells were stained with phalloidin (Alexa Fluor 568
phalloidin, Invitrogen, Carlsbad, USA) for 20min at room
temperature following a further washing step with PBS. As a
last staining step, cells were incubated with DAPI (Sigma) for
2min. Following staining of adherent cells, Petri-dishes were
inspected by ﬂuorescence microscopy at a magniﬁcation of
200x (Zeiss Axio Observer Z1, Germany).
2.11. Viability Test over a Period of 14 Days. For viablity tests,
standard ePTFE vascular prostheses either uncoated or coat-
ed with heparin (FlowLine Bipore and FlowLine Bipore He-
parin, Jotec GmbH, Hechingen, Germany) or ePTFE (Flow-
Line Bipore) coated with Parylene C, diX AM, and oligonu-
cleotieds as described above were used. The three diﬀerently
coated materials were cut into samples and glued with sil-
icone paste into 48-well suspension culture plates. 3 ∗ 104
HUVECs were seeded into each well. After 2.5h, incubation
using continuous agitation (The Belly Button, Stovall Life
Science Inc, Greensboro, USA) medium was exchanged and
nonadherent cells removed. Cell viability was measured with
the alamarBlue assay after 1, 2, 5, 8, 12, and 14 days.
2.12. Hemocompatibility Testing. 12-well Polystyrene plates
and ePTFE patches (Gore-Tex Cardiovascular Patch, W.L.
Gore & Associates, Inc., Flagstaﬀ,A ri z o n a ,U S A )w e r ec o a t e d
withdiXAMandoligonucleotidesasdescribedabove.ePTFE
was cut into 12-well-sized samples and glued into 12-well
suspension culture plates using silicone paste. Human bloodInternational Journal of Biomaterials 5
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Figure 2: Contact angle measurements by the captive bubble
method using PBS. Contact angle was signiﬁcantly lower for
oligonucleotide coated samples compared to diX AM or HEPES
treated samples (∗, P<0.05, n = 6).
samples were obtained from six healthy volunteers following
giving informed consent (approved by the ethical committee
of University Hospital Tuebingen). Whole blood from each
volunteer was collected in heparin precoated monovettes
(1,5IU Liquemin, Roche, Grenzach-Whylen, Germany per
m Lb l o o d ) .T w o1 2 - w e l l si ne a c hg r o u pw e r ei n c u b a t e d
with 3mL donor blood each. After 1h incubation at
37◦C with continuous shaking, the two blood samples of
each group were pooled and further processed using the
following protocols. 2.4mL blood from each group was
added to an EDTA-monovette. Blood cell count, including
platelet count, was performed using a Cobas Micros 60
S/N (Axon Lab, Reichenbach, Germany). 2.8mL blood from
eachgroupwascollectedinaCitrate-monovette.Monovettes
were centrifuged at 2000g for 15min at room temperature.
600μL supernatant was used for thrombin-antithrombin
complex (Enzygnost TAT micro, Dade Behring Marburg,
Germany) and PMN-Elastase determination (Milenia PMN-
Elastase, Milenia Biotec, Germany). 5.4mL blood from
each group was added to 0.3mL of CTAD anticoagulant
monovettes (Becton Dickinson, USA). Tubes were placed
on ice for 15min. Following centrifugation at 2500g for
20min at 4◦C 1.4mL, plasma from the middle fraction
was aspirated and transferred to a new neutral monovette.
After repeated centrifugation, 200μl plasma was used for
determination of β-Thromboglobulin (ASSERACHROM β-
TG Kit, Diagnostica Stago, France).
2.13. Statistics. All quantitative results were expressed as
mean standard deviation. The diﬀerences among groups
were analyzed with one-way ANOVA, and independent sam-
ples t-test was performed between each of two groups in case
of a signiﬁcant statistical diﬀerence existed. P values < 0.05
were considered statistically signiﬁcant.
3. Results
3.1. DiX AM and Oligonucleotide Coating Surface Charac-
terization. Substrates were coated with parylene C as an
intermediate layer and with diX AM as top coating. Coating
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Figure 3: Oligonucleotide coating stability. Polypropylene sheets
were coated with diX AM and oligonucleotides were applied to the
coated surface. Oligonucleotides were detected by an ELISA system.
Samples were exposed to a constant ﬂuid ﬂow inducing at least 9,
5N/m 2 shear stress on the surface for 1h (n = 6).
thicknesses measured by ellipsometry on a simultaneously
coated Si wafer were 550–2200nm for parylene C and 40–
120nm for diX AM, depending on charge deposition param-
eters. The elemental composition in percent of total number
of atoms excluding hydrogen of the surface measured by XPS
was as follows: N-6.2 at.% (theoretically expected for diX
AM-5.9 at.%), C-90.7 at.%, Cl-1.9 at.%, and O-1.2 at.%.
Chlorine is not contained in diX AM but makes up 14.2 at.%
of Parylene C, which was the intermediate layer under diX
AM. Thus, we presume the Cl signal measured by XPS to
originatefromParyleneC.AsthediXAMcoatingwasthicker
than the XPS sampling depth of 5 to 10nm, we interpret
the Cl signal as an indication that the diX AM coating
was not completely closed. Concerning Oxygen content,
amines are generally known to be prone to oxidation. St-
Georges-Robillard [33] have recently investigated oxidation
of diX AM on air and found simultaneous depletion of
amino groups and increase of Oxygen content on a time
scale of several days. The number of chemically available
amino groups on the diX AM surface as determined by ESR
Spectroscopy was 0.94 ±0.331/nm2.
To examine if changed surface wettability has an impact
oncelladhesion,sampleswereanalyzedbythecaptivebubble
method.Samplescoatedbyasingleoligonucleotidesequence
or by the oligonucleotide library had signiﬁcantly lower
contact angles resulting in increased hydrophilic surface
characteristics compared to diX AM (P<0.001; Figure 2).
This was independent of the used buﬀer (HEPES) as the
contact angle for HEPES-treated samples did not diﬀer from
the angle of the diX AM surface.
3.2. Immobilization of Oligonucleotides and Shear Stress Resis-
tance of Adhered Oligonucleotides. On diX AM-coated sur-
faces, immobilized oligonucleotides were detected via ﬂu-
orescence labeling of the oligonucleotides and an ELISA-
System targeting the ﬂuorescence label. After application of
oligonucleotides, four washing steps were applied. Fluores-
cence and absorbance, respectively, were signiﬁcantly higher,
when oligonucleotides were applied to the diX AM surface
(Figure 3, prior to shear stress exposure, data of ﬂuorescence6 International Journal of Biomaterials
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Figure 4: Stability against degradation by human blood serum of on diX AM-immobilized oligonucleotides. No signiﬁcant degradation of
oligonucleotides could be detected after 96h incubation in comparison to the samples without serum incubation (P = 0.079, n = 9).
detection not shown). Immobilization by sole adhesion of
the oligonucleotides on the diX AM-coated surface is pos-
sible.
Oligonucleotideswereexposedtophysiologicshearstress
totestiftheadhesionisstableenoughtowithstandoccurring
shear stresses in vivo. For the assay, a mean wall shear stress
of 9.5N/m2 was chosen, as shear stress on native in vivo
heart valve and artery surfaces are estimated to approximate
8N/m2and 1.5N/m2 [34, 35]. Accordingly, the chosen setup
exceeded the maximum physiologic levels. The used ﬂuid,
Xanthan gum, simulated shear thinning viscosity behavior
and particle characteristics of blood [36, 37]. No signiﬁcant
decrease of oligonucleotide amount on the sheared diX AM
surface could be detected compared to the oligonucleotide
control (P = 0.076; Figure 3).
3.3. Serum Stability of Adhered Oligonucleotides. To exclude
degradation of the applied oligonucelotides by human blood
serum, samples were incubated between 15min and 96h
with human blood serum. The mean values of each time
point diﬀered by ±9.6% from the mean of the sample with-
out serum incubation (Figure 4). No signiﬁcant degradation
ofoligonucleotidescouldbedetectedafter96hincubationin
comparison to the samples without serum incubation (P =
0.079).
3.4. Cell Adhesion and Viability on Oligonucleotide-Coated
diX AM. Cell adhesion experiments were conducted with
diﬀerent cell types in FCS supplied medium (10% for
eEPC and human EC, 2% for HUVEC). DiX AM sam-
ples where ol-igonucleotides with the same sequence, an
oligonucleotide library, HEPES, or nothing of all was
applied were used. Cells of a murine embryonic EPC
cell line (eEPCs) adhered predominantly to areas coated
with either the single oligonucleotide sequence or the
oligonucleotide library (Figure 5(a)). HUVECs and human
EC derived from human saphenous veins showed the
same behavior. In Figure 5(b), the mean number of cells
per mm2 on each coating and cell type is shown. Cell
number on oligonucleotide-coated surfaces was signiﬁcantly
higher than on uncoated diX AM or the HEPES control
(P<0.05). Thus, oligonucleotides enhanced the adhe-
sion of all cell types compared to cell adhesion on diX
AM or buﬀer-treated diX AM. Experiments (n = 9)
containing controls on tissue culture (TC) surface were
conducted with HUVECs. Cell adhesion on oligonucleotide-
coated areas was signiﬁcantly higher than on TC surfaces
(P<0.05), see Figure 6.
To examine the eﬀect of the oligonucleotide coating
on cell adhesion without previous protein deposition from
FCS, eEPC cells were applied to the samples in serum-free
medium or buﬀers. For cells applied to the samples in PBS
without Ca2+/Mg2+, PBS with Ca2+/Mg2+/Glucose or serum-
free eEPC medium no signiﬁcantly enhanced adhesion to
oligonucleotide-coatedareascouldbedetected(Figure 7(a)).
Cells adhered to all samples equally. To further investigate
the eﬀects of FCS diX AM and oligonucleotide-coated Petri-
dishes were preincubated for two hours with FCS sup-
plemented eEPC medium. Medium was removed and 5 ×
104 mouse EPC cells in serum-free medium applied for 2.5h
at 37◦C, 5% CO2 on a three-dimensional orbital shaker. On
Petri-dishes preincubated with FCS-containing medium and
cells applied in serum-free medium, the same behavior of
cell adhesion like in Petri-dishes where cells were applied in
FCS containing medium was observed. Adhesion of cells was
signiﬁcantly higher on oligonucleotide-coated areas then on
control areas (P<0.05, Figure 7(b)).
In a further experiment, it was investigated if the
amount of oligonucleotide used for coating the diX AM
surface plays a role in eﬃciency of cell adhesion. Diﬀerent
concentrations of the single oligonucleotide sequence and
the oligonucleotide library were applied to a diX AM-coated
12-well plate. 5 × 104 m o u s eE P Cc e l l sw e r ea p p l i e dt o
each well in FCS supplied medium and incubated at 37◦C,International Journal of Biomaterials 7
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Figure 5: Cell adhesion to oligonucleotide-coated diX AM surfaces in FCS containing medium under dynamic conditions. Samples were
incubated with 0,05 ∗ 106 cells for 1h in corresponding medium containing FCS. (a): Scale bar equals 200μm. (b): Number of adhered
cells per mm2 was counted in microscopy images (n = 6). Groups marked with ∗ are signiﬁcantly diﬀerent to HEPES and diX AM samples
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Figure 7: Inﬂuence of FCS on cell adhesion on oligonucleotide coated diX AM surfaces. (a) Samples were incubated with 0,05 ∗ 106 eEPC
cells for 2,5 h under dynamic conditions in medium or buﬀer without FCS. Cell number was counted in microscopy images (n = 6).
ANOVA tests revealed no signiﬁcant diﬀerence between the groups. (b) Samples were preincubated with eEPC Medium containing FCS for
2h .A f t e r w a r d s0 , 0 5∗ 106 eEPC cells were applied for 2,5h under dynamic conditions in medium without FCS. Cell number was counted
in microscopy images (n = 6). Groups marked with ∗ are signiﬁcantly diﬀerent to HEPES and diX AM samples (P<0.05).
5%·CO2. After 1h, all the nonadherent cells were washed
oﬀ and the adherent cells incubated for a further 22 hours.
After 22 hours, cell number was determined via the ala-
marBlue Assay. There was no signiﬁcant diﬀerence between
the samples with diﬀerent oligonucleotide concentrations
visible (Figure 8). Also, the utilization of a single sequence
or of a library did not make any signiﬁcant diﬀerence;
but a signiﬁcant diﬀerence in number of adhered cells
was observed between oligonucleotide-coated samples and
samples coated with diX AM only or on diX AM samples
treated with buﬀer (HEPES) only (P<0.05).
To further characterize cell adhesion, samples were in-
cubatedwithHUVECsfor1handadherentcellswerestained
for Vinculin, CD49e (Integrin alpha 2 subunit) and F-Actin.
Cells on oligonucleotide-coated surfaces showed a ﬂat mor-
phology and covered a bigger area than cells on diX AM
control surfaces which showed a spherical morphology
(Figure 9). Cell morphology on oligonucleotide-coated sur-
faces was similar to cell morphology on TC (tissue culture)
surfaces. Cell density was higher on oligonucleotide-coated
surfaces and on TC surfaces as on these surfaces more cells
adhered than on diX AM control surfaces.
Viability of HUVECs over a period of 14 days was com-
pared between two standard vascular prosthetic materials,
ePTFE and ePTFE coated with heparin, and the newly
developed coating, diX AM and oligonucleotides on ePTFE.
Cell viability was signiﬁcantly higher on oligonucleotide-
coated ePTFE for all time points compared to ePTFE and
ePTFE coated with heparin (Figure 10). 2.5h after adding
of cells, nonadherent cells were removed. Values for viability
on day one after seeding are an indicator for cell adhesion
promoting characteristics. Adhesion of HUVECs was sig-
niﬁcantly higher on oligonucleotide-coated ePTFE than on
ePTFE or ePTFE with heparin. On all materials measured
values for viability decreased over time. After 5 days, no
viable cells could be detected on ePTFE any more. On ePTFE
withheparinviabilitydecreasedonday14to13 ±10%ofthe
value of day one. On ePTFE with oligonucleotides viability
onday14wasstill43 ±5%ofviabilitymeasuredondayone.
3.5. Hemocompatibility. Uncoated ePTFE, diX AM coated
suspension cell culture plates and diX AM- and oligonuc-
leotide-coated ePTFE samples were incubated with human
b l o o df o r1ha t3 7 ◦C on an orbital shaker. As negative con-
trol, wells of a suspension cell culture plate were used. The
experiment was repeated with six diﬀerent blood donors. To
quantify cell adhesion platelets, erythrocytes and leucocytes
were counted in blood samples following incubation.International Journal of Biomaterials 9
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Figure 9: Staining for Vinculin, CD49e and F-Actin of HUVECs after 1h hour incubation in FCS containing medium under dynamic
conditions. Samples were incubated with 0,05 ∗ 106 cells in medium containing FCS. Nonadherent cells were removed before staining. Scale
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Figure 10: Viability of HUVECs on standard blood vessel graft
materials (ePTFE and ePTFE coated with heparin) and on ePTFE
coated with diX AM and oligonucleotides over a period of 14
days. Metabolic activity of cells was signiﬁcantly higher for each
time point on oligonucleotide-coated ePTFE compared to ePTFE
or ePTFE with heparin (P<0.05).
ANOVA tests revealed no signiﬁcant decrease in number
and therefore no signiﬁcant adhesion to any of the samples
(Figure 11). Surface-dependent activation of platelets and
leukocytes was measured by determination of released β-
thromboglobuline (β-TG) and PMN-elastase, respectively.
β-TG is stored in the α-granules of platelets and released
in large amounts after platelet activation. The release of
polymorphonuclear- (PMN-)elastase takes place after acti-
vation of neutrophile granulocytes or collapse of these cells.
It is broadly used to measure granulocyte activity during
inﬂammatory response. Values for β-TG for oligonucleotide
coated and uncoated dix AM surfaces did not diﬀer sig-
niﬁcantly from negative control (P>0.05). PMN-elastase
was released to a higher extent by oligonucleotide-coated
diX AM surfaces but there was no signiﬁcant increase com-
pared to the negative control (P>0.05). Surface-dependent
activation of the coagulation system was detected by mea-
suring thrombin-antithrombin III (TAT). TAT is an inactive
proteinase/inhibitor complex resulting from thrombin and
its inhibitor antithrombin III. An increased TAT level is an
indicator for thrombotic events. TAT level was not signi-
ﬁcantly increased for any of the samples (P>0.05).
4. Discussion
Interfaces between implant surfaces and recipient tissue or
blood play a crucial role for long-term performance and
patency of cardiovascular implants. This study analyzed a
novel oligonucleotide-coated diX AM layer in terms of
coating stability, EC and EPC adhesion and viability under
continuous shear stress application and hemocompatibility.
These criteria were chosen as representative key characteris-
tics for cardiovascular implants. Application of the coating
concept for other implants is also conceivable.
The oligonucleotide coating showed excellent adhesion
properties forhumanEC and murine EPCunder continuous
shear stress application as well as good viability properties
over a period of 14 days for HUVECs. Cell morphology of
HUVECs after adhesion on oligonucleotide-coated surfaces
was similar to cell morphology of cells adhered to tissue
culture surfaces. This qualiﬁes the material for in vivo
endothelialization either by EC migration from adjacent
native tissue or by EPC capture and adhesion from the
blood stream. Stability of the oligonucleotides coated on the
diX AM layer was excellent. The applied oligonucleotides
withstandshearstressintheamountofshearstressoccurring
in blood vessels in vivo. Additionally, the oligonucleotides
were not degraded by human blood serum during prolonged
exposure of 96 hours. Maintained hemocompatibility was
conﬁrmed by testing for thrombocyte, granulocyte, and
coagulation system activation.
A combination of two parylenes, with an intermediate
layer of Parylene C and the outer layer of diX AM, an amino-
modiﬁed parylene derivate, was chosen as a protection ﬁlm
between synthetic material and tissue or blood, as polymers
of the parylene family are known to oﬀer good elasticity, bio-
stability and biocompatibility and can be coated easily to
diﬀerentsubstratematerialsevenofirregularshape.Parylene
C coatings are currently used as protection ﬁlms for biomed-
ical devices, for example, metal stents, implantable electrode
probes,andelectroniccircuitries[25,26,38].Thelimitations
of Parylene C for cardiovascular and other tissue engineering
approaches are the low cell adhesion characteristics [27, 39].
Other parylene derivates such as diX AM oﬀer better growth
capacities [39]. Even so we observed low adhesion rates of
cells to diX AM-coated areas. Additional coating of diX AM
with oligonucleotides enhanced cell adhesion signiﬁcantly
and allowed stable and conﬂuent growth of the cells.
Theseoligonucleotideswererobustlyimmobilizedonthe
diX AM surface. Shear stress up to 9,5N/m2 was applied to
the samples, which exceeded the maximum shear stresses
observed in blood vessels and heart valves [34, 35, 40].
Xanthan gum was used in the shear stress test ﬂuid to
simulate rheological properties of blood [36, 37]. Shear
stress stability is crucial as denuded implants exhibit highly
thrombotic surface characteristics. Also, DNA molecules
may be easily degraded and their solubility in aqueous solu-
t i o n si sh i g h[ 19]. This was not observed in the present
study. After immobilization on diX AM, the oligonucleotides
were retained in both the aqueous solutions used in the
shear experiments and during incubation with human blood
serum.
Interestingly, it did not matter whether a single sequence
or an entire oligonucleotide library was used, both enhanced
cell adhesion equally. The mechanism of enhanced attach-
ment, therefore, is more likely to be dependent on the overall
characteristics of DNA-oligonucleotides than on a speciﬁc
sequence. As cells were only able to adhere, when they were
added to the oligonucleotide-coated surface in FCS supplied
medium or when the coated samples were preincubated in
medium containing FCS, the mechanism of enhanced cell
attachment maybe mediated through attachment-facilitating
serum proteins deposited on the surface from FCS. It has
been reported in the literature that deposition of serumInternational Journal of Biomaterials 11
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Figure 11: Hemocompatibility testing of oligonucleotide coated diX AM surfaces. Samples were incubated with human whole blood for 1 h
at 37◦C under continuous shaking. Cell number and diﬀerent factors, which give information about the activation of thrombocytes (β-TG),
granulocytes (PMN-Elastase) and the coagulation system (TAT) were measured in the supernatant. ANOVA tests revealed no signiﬁcant
diﬀerence between the groups (P>0.05, n = 6).
proteinslikeﬁbronectinandvitronectincontainedinserum-
supplemented culture medium on cell culture material sur-
faces mediates initial cell attachment, spreading, and behav-
ior [41, 42]. No enhanced cell adhesion could be detected for
serum-free medium or PBS. Even supplementation of PBS
with calcium, which plays a major role in adhesion via cad-
herins [43, 44] did not favor cell adhesion. Oligonucleotide
coating obviously changes surface properties in a way that
facilitates adsorption of functional proteins. A factor that
was shown to aﬀect protein adsorption is surface wettability.
Protein adsorption is usually higher on hydrophobic surfaces
[45, 46], but protein function is presumably maintained
better after adhesion to hydrophilic substrates [47–51]. The
oligonucleotide coating changes surface wettability to a more12 International Journal of Biomaterials
hydrophilic condition compared to the diX AM coating as
shown by contact angle measurements. This corresponds to
the observed enhanced cell adhesion. Therefore, the more
hydrophilic oligonucleotide surface may be involved in this
phenomenon, but other determinants such as surface charge
might also play a role in cell attachment and hemocom-
patibility. The ability of materials to adsorb proteins (in an
active state) from serum determines their ability to support
cell adhesion and spreading [52] and, hence, is an important
aspect of their biocompatibility. It will be very interesting to
further characterize this adsorption in a future work.
Viability of the adhered cells was measured over a time
period of 14 days. As a high number of cells were used for
seeding, samples were assumed to be conﬂuent on day one.
Viability on oligonucleotide-coated samples decreased to 43
±5%onday14.AsthealamarBlueassaysmeasuremetabolic
turnover, this might be due to less metabolic activity as
further cell proliferation might not have been possible.
Measured viability on ePTFE and ePTFE with heparin de-
creased more dramatically. In these cases, cell loss is
probable. ePTFE coated with diX AM and oligonucleotides,
therefore, showed considerably improved properties for
cell growth. Additionally, the similar cell morphology of
HUVECs adhered on oligonucleotide-coated surfaces like on
tissue culture surfaces as shown by staining for Vinculin,
CD49e, and F-Actin conﬁrms the good properties for endo-
thelial cell growth of oligonucleotide-coated surfaces.
For blood contacting material, hemocompatibility is a
further important point. Many surface modiﬁcations used
for engineering of material interfaces for EC adhesion that
bind EC also will bind platelets and initiate thrombosis.
Here, we provide data, demonstrating that the adhesion of
erythrocytes, thrombocytes, and leucocytes was low to the
oligonucleotide-coated ePTFE. This is an indication that ol-
igonucleotide-coated diX AM surfaces do not activate
inﬂammatory or thrombogenic responses. The measured
values conﬁrmed this result by not showing any activation
ofthrombocytes(β-TG),granulocytes(PMN-elastase)orthe
coagulation system (TAT) by oligonucleotide-coated ePTFE.
Values for all examined variables were in the same range as
the values for clinically routinely used standard ePTFE mate-
rial(Gore-TexCardiovascularPatch,W.L.Gore&Associates,
Inc., Flagstaﬀ, Arizona, USA). Furthermore, the determined
values were in a similar range as known values for materials
with excellent hemocompatibility previously published: β-
TG ranges around 500IU/mL for biopassive or active coated
membraneoxygenators(JostraQuadrox,MaquetCardiopul-
monary, Hirrlingen, Germany) [53], glutaraldehyde-ﬁxed
pericardium [54] or star-PEG-modiﬁed substrates [55].
Values for PMN-elastase in literature range between 300–
400μg/Lforcoatedmembraneoxygenators[53,56].Datafor
TAT revealed levels of 6–8μg/L for star-PEG-coated surfaces
[55] and nitinol stents [57]. Positive controls are known to
range between 2300–6000IU/mL for β-TG [53–55], 450–
1000μg/L for PMN-elastase [53, 56], and 500–6000μg/L for
TAT [55, 57]. Other studies have reported nonimmunogenic
characteristics of oligonucleotides [15, 17, 18]. This might
be due to their small size and their natural occurrence
in the human body thus being no foreign body material
[15, 16]. Advantages of oligonucleotides as coating material
are easy synthetization and many functional groups for
coupling of additional molecules, such as growth factors.
The amino groups of the diX AM surface can also be
utilized for molecule coupling. We determined an amount
of free amino groups on diX AM polymer coating of about
1 million per μm2. To conﬁrm the applicability of the
presented DNA coating for in vivo endothelialization of
cardiovascular implants, further experiments to clarify the
adhesion properties of EC and EPC in human blood vessel
environment conditions are required. As diX AM can be
coated to substrates of various shapes and material, the
coating process can be easily transferred to currently used
vessel graft materials. In this work, we developed the suc-
cessful coating of ePTFE with diX AM and oligonucleotides
by surface activation using microwave plasma processing
and subsequent chemical vapour deposition of diX AM and
oligonucleotide adsorption.
This study revealed DNA-oligonucleotides coated to diX
AM surfaces as attractive coating materials for cardiovas-
cular implants. They are shear resistant, nondegradable by
human blood serum, oﬀer excellent adhesion properties
for EC, and are hemocompatible. Furthermore, they might
support adhesion of circulating EPC or transanastomotic
ingrowth of EC. This opens new opportunities for the
manufacturing of “oﬀ-the-shelf” cardiovascular implants
to achieve in vivo endothelialization after implantation.
Additionally, immobilization of oligonucleotides on other
types of implants, for example, orthopedic tissues might
enhance their incorporation into surrounding tissues.
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